A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 601 participants.
Also called NCT02207374
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 601 participants
- Sponsor
- Registry
-
NCT02207374
-
- Main results
- Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02207374. Randomized; no masking; primary purpose treatment. Start 2014-08-04 (actual); primary completion 2016-02-27 (actual). Results posted on 2019-01-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes
- Acronym
- SUSTAIN™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- DPP-4 inhibitor
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02207374- Content hash
8db8ba94c08071cb9755780bb8713e5aa15b6779059430aa482286bc0ed9baba